Bandingkan Harga & Kinerja Organon Pharma Indonesia Tbk. (SCPI) vs Reksa Dana Indeks Premier ETF FTSE Indonesia ESG (XIFE)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Organon Pharma Indonesia Tbk. dan Reksa Dana Indeks Premier ETF FTSE Indonesia ESG: Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M), sedangkan Reksa Dana Indeks Premier ETF FTSE Indonesia ESG diperdagangkan di Rp95 (kapitalisasi pasar 31,23 M, volume 24 jam 9,4 rb). Perbedaan utamanya: Organon Pharma Indonesia Tbk. jauh lebih besar — sekitar 3,3× kapitalisasi pasar Reksa Dana Indeks Premier ETF FTSE Indonesia ESG. Mana yang lebih baik tergantung tujuan investasimu.
| SCPI | XIFE | |
|---|---|---|
Kapitalisasi Pasar | 104,4 M | 31,23 M |
Volume | — | 9,4 rb |
Lot | — | 94 |
Perputaran | — | 893 rb |
Harga Rata-rata | — | 95 |
Nilai Transaksi | — | 893 rb |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
